A carregar...
Publicação
European network on optimizing treatment with therapeutic antibodies in Chronic Inflammatory Diseases: Overview, progress and perspectives
| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 6.21 MB | Adobe PDF |
Orientador(es)
Resumo(s)
Treatment of chronic inflammatory diseases has been revolutionized with the introduction of targeted therapies using therapeutic antibodies. However, a large proportion of patients do not respond to treatment, or they lose response over time. To overcome this challenge, researchers have started to investigate strategies for treatment optimization, based on the development of patient stratification tools and therapeutic drug monitoring (TDM). The aim of the COST Action European Network on Optimizing Treatment with Therapeutic Antibodies in chronic inflammatory diseases (ENOTTA) is to create an interdisciplinary, pan-European network to defragment and structure scientific research in this field. Through the network, ENOTTA will facilitate the implementation of tools for patient stratification, as well as individualized (TDM-guided) approaches. These strategies should be cost-effective and provide therapeutic antibody treatment optimization for the treatment of chronic inflammatory diseases. This article highlights the key achievements of the ENOTTA consortium to date.
Descrição
Palavras-chave
Chronic inflammatory diseases COST action CA21147 ENOTTA Therapeutic antibodies Therapeutic drug monitoring
Contexto Educativo
Citação
Tachkov, K., Rumano, M., Bluett, J., Bogavac-Stanojević, N., Dreesen, E., Itik, M., Kararigas, G., Kawalec, P., Santos, M., Skrede, S., Petrova, G., & Mulleman, D. (2026). European network on optimizing treatment with therapeutic antibodies in Chronic Inflammatory Diseases: Overview, progress and perspectives. Clinical and Translational Science, 19(6), e70643. https://doi.org/10.1111/cts.70643
Editora
Wiley/ASCPT